Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ipilimumab Clear all
Terminated Phase 1Phase 2 Interventional Results available

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

NCT03663166
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Thoracic Radiotherapy, Platinum Based Chemotherapy, ipilimumab, Nivolumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 25, 2026, 9:20 PM EDT
Terminated Phase 1 Interventional

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

NCT03597282
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
NEO-PV-01, Nivolumab, Adjuvant, APX005M, ipilimumab
Biological · Other
Lead sponsor
BioNTech US Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 25, 2026, 9:20 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

NCT02736123
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab - Arm A, Nivolumab + Ipilimumab - Arm B
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 25, 2026, 9:20 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

NCT03430791
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Nivolumab 240 mg IV, Nivolumab 3 mg/kg, Ipilimumab 1 mg/kg, NovoTTF200A (Optune)
Drug · Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 25, 2026, 9:20 PM EDT
Terminated Phase 1 Interventional

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

NCT04967196
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 25, 2026, 9:20 PM EDT
Active, not recruiting Phase 2 Interventional

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

NCT03449108
View directory record Official record
Conditions
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer
Interventions
Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Cyclophosphamide, Fludarabine, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 9:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

NCT04319224
View directory record Official record
Conditions
Cancer
Interventions
Vopratelimab, Ipilimumab, Nivolumab
Drug
Lead sponsor
Jounce Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 25, 2026, 9:20 PM EDT
Completed Phase 2 Interventional

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT04817254
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Malignant Glioma
Interventions
TMZ, ipilimumab 3mg/kg, Nivolumab, ipilimumab 1mg/kg
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 25, 2026, 9:20 PM EDT
Active, not recruiting Phase 2 Interventional

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

NCT04013854
View directory record Official record
Conditions
Melanoma Stage III, Melanoma
Interventions
nivolumab, Ipilimumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Lancaster, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

NCT01750580
View directory record Official record
Conditions
CANCER, NOS
Interventions
Lirilumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Tampa, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 25, 2026, 9:20 PM EDT
Terminated Phase 1 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02408861
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 25, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

NCT03956680
View directory record Official record
Conditions
Advanced Solid Cancers
Interventions
BMS-986301, Nivolumab, Ipilimumab
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 25, 2026, 9:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

NCT01740297
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene laherparepvec, Ipilimumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
32
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 25, 2026, 9:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415
View directory record Official record
Conditions
Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma
Interventions
PF-08634404, Ipilimumab, Axitinib, Casdatifan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
160
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 101 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 9:20 PM EDT
Active, not recruiting Phase 1 Interventional

Surgical Nivolumab And Ipilimumab For Recurrent GBM

NCT04606316
View directory record Official record
Conditions
Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
Interventions
Nivolumab-Placebo, Nivolumab, Ipilimumab-Placebo, Ipilimumab, Surgery
Drug · Procedure
Lead sponsor
Gilbert Youssef
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT01998126
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Ipilimumab, Erlotinib, Crizotinib, Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 25, 2026, 9:20 PM EDT
Recruiting Phase 2 Interventional

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

NCT04933903
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ipilimumab, Nivolumab, SBRT
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 25, 2026, 9:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

NCT03749460
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung, Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IVA Major Salivary Gland Cancer AJCC v8, Stage IVB Major Salivary Gland Cancer AJCC v8, Stage IVC Major Salivary Gland Cancer AJCC v8
Interventions
Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 25, 2026, 9:20 PM EDT
Terminated Phase 2 Interventional Results available

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

NCT03724968
View directory record Official record
Conditions
Metastatic Melanoma, Advanced Melanoma, Metastatic Melanoma Stratified by MHC-II Expression
Interventions
Nivolumab, Relatlimab, Ipilimumab
Drug
Lead sponsor
Elizabeth Davis
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 25, 2026, 9:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00323882
View directory record Official record
Conditions
Prostate Cancer, Neoplasm Metastasis
Interventions
MDX-010
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 25, 2026, 9:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

NCT03241173
View directory record Official record
Conditions
Advanced Malignancies
Interventions
INCAGN01949, Nivolumab, Ipilimumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 25, 2026, 9:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

NCT05921760
View directory record Official record
Conditions
IDH1-mutant Cholangiocarcinoma
Interventions
Ivosidenib, Nivolumab, Ipilimumab
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 25, 2026, 9:20 PM EDT
Recruiting Phase 2 Interventional

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382
View directory record Official record
Conditions
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
580
States / cities
Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 9:20 PM EDT
Terminated Phase 2 Interventional

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

NCT05715229
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 25, 2026, 9:20 PM EDT